Sherlock Biosciences Raises Series A Round
Posted on 04/23/2019
Sherlock Biosciences is a company working on improving diagnostic technology. Sherlock Biosciences raised over US$ 31 million in a Series A round from investors such as Northpond Ventures, Baidu Ventures, the Open Philanthropy Project, and other investors. The Open Philanthropy Project gave a US$ 17.5 million non-dilutive grant.
Sherlock Biosciences launched its Sherlock product in March 2019. According to the press release, “The funds will be used to advance development programs for Sherlock’s core platform technologies. These include SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), a method for identifying specific sequences of genetic material in a sample using CRISPR; and INSPECTR (INternal Splint-Pairing Expression Cassette Translation Reaction), which can be programmed to distinguish targets based on a single nucleotide at room temperature, without laboratory equipment.”